| Year |
Citation |
Score |
| 2021 |
Palve V, Knezevic CE, Bejan DS, Luo Y, Li X, Novakova S, Welsh EA, Fang B, Kinose F, Haura EB, Monteiro AN, Koomen JM, Cohen MS, Lawrence HR, Rix U. The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors. Cell Chemical Biology. PMID 34329582 DOI: 10.1016/j.chembiol.2021.07.008 |
0.414 |
|
| 2016 |
Knezevic CE, Wright G, Remsing Rix LL, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chemical Biology. PMID 27866910 DOI: 10.1016/J.Chembiol.2016.10.011 |
0.347 |
|
| 2015 |
Knezevic C, Wright G, Kuenzi B, Rix LR, Luo Y, Lawrence H, Rix U. Abstract A71: Differential proteome-wide target profiles of clinical poly(ADP-ribose) polymerase inhibitors in breast cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A71 |
0.411 |
|
| 2013 |
Granger BA, Jewett IT, Butler JD, Hua B, Knezevic CE, Parkinson EI, Hergenrother PJ, Martin SF. Synthesis of (±)-actinophyllic acid and analogs: applications of cascade reactions and diverted total synthesis. Journal of the American Chemical Society. 135: 12984-6. PMID 23972114 DOI: 10.1021/Ja4070206 |
0.477 |
|
| 2012 |
Dunstan MS, Barkauskaite E, Lafite P, Knezevic CE, Brassington A, Ahel M, Hergenrother PJ, Leys D, Ahel I. Structure and mechanism of a canonical poly(ADP-ribose) glycohydrolase. Nature Communications. 3: 878. PMID 22673905 DOI: 10.1038/Ncomms1889 |
0.557 |
|
| 2012 |
Finch KE, Knezevic CE, Nottbohm AC, Partlow KC, Hergenrother PJ. Selective small molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG). Acs Chemical Biology. 7: 563-70. PMID 22220926 DOI: 10.1021/Cb200506T |
0.387 |
|
| Show low-probability matches. |